Creating a Robust Pricing Compliance/Audit Program That Will Provide the Most Accurate Calculations and the Ability to Verify Them
11 March 2009
Foley Partner Lena Robins is speaking at the American Conference Institute’s (ACI) 7th Annual Advanced forum on Government Regulation of Prescription Drug Pricing, March 11 – 12, 2009 in New York, New York.
Ms. Robins is speaking on March 11, 2009 at 4:15 p.m. Her session is titled “Creating a Robust Pricing Compliance/Audit Program That Will Provide the Most Accurate Calculations and the Ability to Verify Them.” Topics to be covered include:
- Developing a compliance program that conforms to HHS OIG draft Compliance Program Guidance for the pharmaceutical industry
- Reducing risk in the three areas identified by the OIG as the most problematic:
- integrity of data
- kickbacks and illegal remuneration
- samples
- integrity of data
- Defining the relationship between the government pricing function and the compliance department
- what role does or should the finance department play?
- Weighing the pros and cons of outsourcing calculations
- what can or should be outsourced?
- ensuring that outsources calculations are correct
- what is the government’s position on outsourcing calculations?
Related Insights
12 March 2025
Health Care Law Today
Compounded GLP-1 Drugs: Texas Judge Denies PI Motion and Request for Stay of FDA’s Declaration that Tirzepatide Shortage is Resolved; Plaintiff OFA Appeals
On March 5, 2025, one U.S. District Court ruled unequivocally in the Food & Drug Administration’s (FDA) favor in the case, Outsourcing Facilities Ass’n, et. al. v. U.S. Food and Drug Admin., et. al., 4:24-cv-0953-P, slip op., 2025 WL 746028, at *15 (N.D. Tex. Mar. 5, 2025), denying plaintiffs’ motion for (1) a preliminary injunction (PI) prohibiting the FDA from taking action against Outsourcing Facilities Association (OFA) members and FarmaKeio based on their compounding of the drug ingredient tirzepatide pending final judgment in the case and (2) a stay pending conclusion of the review proceedings in response to the FDA’s declaration that the shortage of the diabetes and weight-loss tirzepatide products has been resolved.
12 March 2025
Health Care Law Today
GLP-1 Receptor Agonists and Patent Strategy: Securing Patent Protection for New Use of Old Drugs
GLP-1 receptor agonists were initially approved for diabetes treatment (e.g., Ozempic®) but have revolutionized weight management (e.g., Wegovy®) and are now being explored for treating a wide range of health conditions.
11 March 2025
Consumer Class Defense Counsel
No Harm, No Foul: Greenwashing Lawsuit Dismissed for Lack of Article III Standing
It is well-settled that under Article III of the Constitution, United States federal courts are limited to trying “cases and controversies.”